HLA-DRA and pancreatic neoplasm: Using TCGA pancreatic cancer data, we found that between KRAS wild-type and mutants, there was a significant difference in the HIST2H2AA3 expression level (p = 0.001), but not in that of LUZP6 (p = 0.5) or HLA-DRA (p = 0.06) (Figure 6).